Wound treatment is a substantial area of healthcare spending. UK health service alone spends $5.3 billion annually on managing wounds and their associated comorbidities.
The market for wound management techniques is vast. Bandages, negative pressure, and specialized dressings are the main methods used for chronic wounds.
A fast, effective, and affordable option for wound healing
Tel Aviv, Israel-based wound management company RedDress has introduced an innovative blood-based technology to treat chronic wounds. This proprietary approach offers several advantages, including an exceptionally low risk of rejection and significantly enhanced cost-effectiveness compared to traditional methods.
RedDress’ ActiGraft technology also enables the rapid creation of an in-vitro blood clot using patients’ own blood.
The importance of blood clots in healing
Blood clots play a crucial role in the body’s natural healing process. However, in cases of chronic wounds caused by conditions such as diabetes, impaired blood flow prevents the formation of necessary clots and hinders the healing process.
RedDress’ ActiGraft technology recreates the body’s natural healing process by enabling clot formation in chronic wounds where blood flow is impaired. The ActiGraft product family is effective for various chronic wounds, including diabetic ulcers, venous ulcers, pressure injuries, and more.
Effectiveness of ActiGraft
Compared to the standard method of care, ActiGraft has demonstrated a remarkable 72 percent rate of complete wound closure at the 12-week mark, surpassing the standard’s achievement of only 22 percent.
